Tempus AI (TEM) agreed to acquire cancer test maker Personalis (PSNL) in a $1.5 billion deal that Needham said offers a premium well above the comparable group.
Tempus AI will acquire all outstanding shares of Personalis it doesn't already own, for $16.25 per share, offering a floating exchange ratio capped at 0.3356 Tempus shares, the companies said Monday.
The $16.25-per-share consideration represents a 6% premium to Friday's closing price and a 28% premium to the 30-day average price, according to the companies. Tempus AI retains the option to pay up to 50% of the consideration in cash.
The proposed acquisition values Personalis at a forward enterprise value-to-sales multiple of 15.5, which is well above the median for its small- and mid-cap growth peers, Needham said in a note Monday.
"We believe the premium is warranted given the strong test volume growth seen in NeXT Personal, multiple Medicare reimbursement wins (breast, lung cancer, and immunotherapy monitoring), and large addressable minimal residual disease market," Needham analysts said.
About 2.1 million people are expected to be diagnosed with cancer in the US this year, reinforcing the need for long-term monitoring, the companies said. Personalis' NeXT personal cancer test uses minimal residual disease, or MRD, technology.
The acquisition expands Tempus' capabilities in MRD, supporting patients from diagnosis to monitoring, according to the statement.
"Through our existing collaboration with Personalis, we have already demonstrated the strength of combining highly sensitive MRD technology with our commercial infrastructure," Tempus AI Chief Executive Eric Lefkofsky said. "With clinical adoption and reimbursement momentum building, we are collectively well positioned to capture this opportunity, which makes this acquisition particularly exciting."
The transaction is expected to close late in 2026 or early 2027, subject to Personalis shareholder approval and regulatory clearance.
"We think competing bids and potential antitrust issues are unlikely," according to the Needham note. "As a result, we are downgrading (Personalis) shares to hold from buy."
Tempus AI shares fell 6.5% in Monday afternoon trading, while Personalis slumped 13%.
"We are confident Tempus' offer provides the most value to our shareholders and the fastest path to bringing Personalis' industry-leading tests to patients suffering from cancer," Personalis CEO Chris Hall said.
Last year, Tempus AI acquired genetic testing company Ambry Genetics, precision research platform Deep 6 AI and digital pathology developer Paige.
Price: $48.97, Change: $-3.50, Percent Change: -6.67%
